Allelic loss of 10q23.3, the PTEN gene locus in cervical carcinoma from northern Indian population

Pathology and Oncology Research

Volumn 18, Issue 2, 2012, Pages 309-313

  Rizvi, M Moshahid Alam ^a   Alam, M Shabbir ^a,b   Mehdi, Syed Jafar ^a   Ali, Asgar ^a   Batra, Swaraj ^c  

^a JAMIA MILLIA ISLAMIA CENTRAL UNIVERSITY   (India)

^b JAZAN UNIVERSITY   (Saudi Arabia)

^c LNJP/MAMC Campus ^*  (India)

Author keywords

Cervical carcinoma; Loss of heterozygosity; Squmaous cell carcinoma; Tumor suppressor gene

Indexed keywords

DNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ADULT; ALLELE; ALLELIC IMBALANCE; ARTICLE; CANCER STAGING; CHROMOSOME 10Q; CHROMOSOME LOSS; CONTROLLED STUDY; DNA FLANKING REGION; DNA ISOLATION; FEMALE; GENE FUNCTION; GENE LOCUS; HETEROZYGOSITY LOSS; HETEROZYGOTE DETECTION; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; INDIA; MAJOR CLINICAL STUDY; MICROSATELLITE MARKER; PATHOGENESIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PTEN GENE; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CARCINOMA;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CERVIX UTERI; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 10; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDIA; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; MIDDLE AGED; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PTEN PHOSPHOHYDROLASE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; UTERINE CERVICAL NEOPLASMS;

EID: 84863468805     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-011-9446-z     Document Type: Article

References (38)

1. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70
2. Lin JC, Scherer SW, Tougas L, Traverso G, Tsui LC, Andrulis IL, Jothy S, Park M (1996) Detailed deletion mapping with a refined physical map of 7q31 localizes a putative tumor suppressor gene for breast cancer in the region of MET. Oncogene 13:2001-2008
3. Knudson AG (1993) Antioncogenes and human cancer. Proc Natl Acad Sci USA 90:10914-10921
4. Marshall CJ (1991) Tumor suppressor genes. Cell 64:313-326
5. Goddard AD, Solomon E (1993) Genetic aspects of cancer. In: Harris CC, Hirschorn K (eds) Advances in human genetics. Plenum Press, New York 21: 321-376.
6. Siebert R, Gesk S, Harder S, Plötz S, Matthiesen P, Grote W, Schlegelberger B, Jandrig B, Grasmo-Wendler U, Scherneck S, Rosenwald A, Ott G (1998) Deletions in the long arm of chromosome 10 in lymphomas with t(14;18): A Pathogenetic Role of the Tumor Suppressor Genes PTEN/MMAC1 and MXI1? Blood 92(11):4487-4489
7. Steck PA, Lin H, Langford LA, Jasser SA, Koul D, Yung WK, Pershouse MA (1999) Functional and molecular analyses of 10q deletions in human gliomas. Genes Chromosomes Cancer 24 (2):135-143
8. Matsuyama H, Pan Y, Yoshihiro S, Kudren D, Naito K, Bergerheim USR, Ekman P (2003) Clinical significance of chromosome 8p, 10q, and 16q deletions in prostate cancer. Prostate 54(2):103-111
9. Li YL, Tian Z, Wu DY, Fu BY, Xin Y (2005) Loss of heterozygosity on 10q23.3 and mutation of tumor suppressor gene PTEN in gastric cancer and precancerous lesions. World J Gastroenterology 11(2):285-288
10. Sankaranaryanan R, Buduk AM, Rajkumar R (2001) Effective Screening Programmes for Cervical Cancer in low- and middleincome developing countries. Bull World Health Organ 79:954-962
11. Ferlay J. GLOBOCAN 2002. Cancer incidence, mortality and prevalence worldwide. IARC 2004; CancerBase No.5, Version 2.0. IARC Press, Lyon.
12. NATIONAL CANCER REGISTRY PROGRAMME (2007) Consolidated report of hospital based cancer registries 2001-2003. ICMR, New Delhi
13. American Cancer Society. Facts & Figures 2009.
14. Mitra AB, Murty VVVS, Li RG, Pratap M, Luthra UK, Chaganti RSK (1994) Allelotype analysis of cervical carcinoma. Cancer Res 54:4481-4487
15. Jones MH, Koi S, Fujimoto I et al (1994) Allelotype of uterine cancer by analysis of RFLP and microsatellite polymorphisms: frequent loss of heterozygosity on chromosome arms 3p, 9q, 10q, and 17p. Genes Chromosomes Cancer 9:119-123
16. Miayani K, Furugen Y, Matsumoto T, Iwabuchi K, Hirose S, Kinoshita K, Fujii H (2004) Loss of heterozygosity analysis in uterine cervical adenocarcinomas. Gynecol Oncol 94:115-120
17. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP (1998) PTEN is essential for embryonic development and tumour suppression. Nat Genet 19:348-355
18. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R (1997) PTEN: a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science 275:1943-1947
19. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J (1998) Negative regulation of PKB/Aktdependent cell survival by the tumor suppressor PTEN. Cell 95:29-39
20. Reid AHM, Attard G, Ambroisine L, Fisher G, Kovacs G, Brewer D, Clark J, Flohr P, Edwards S, Berney DM, Foster CS, Fletcher A, Gerald WL, Møller H, Reuter VE, Scardino PT, Cuzick J, de Bono JS, Cooper CS (2010) Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer 102:678-684
21. Izycka-Swieszewska E, Brzeskwiniewicz M, Wozniak A, Drozynska E, Grajkowska W, Perek D, Balcerska A, Klepacka T, Limon J (2010) EGFR, PIK3CA and PTEN gene status and their protein product expression in neuroblastic tumours. Folia Neuropathol 48(4):238-245
22. Aneta JJ, Bożena K, Cyprian G, Urszula N (2010) TP53 mutations in endometrial cancers: relation to PTEN gene defects. Int J Gynecol Cancer 20(2):196-202
23. Shabbir Alam M, Rizvi MMA (2011) Cancer of the uterine cervix and PTEN tumor suppressor gene. Lambert Academic Publishing, Germany
24. Kurose K, Zhou XP, Araki T, Eng C (2000) Biallelic inactivating mutations and an occult germline mutation of PTEN in primary cervical carcinomas. Genes Chromosomes Cancer 29:166-172
25. Benedet JL, Bender H, Jones H III, Ngan HYS, Pecorelli S (2000) FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int J Gynecol Obstet 70:209-262
26. Sambrook J, Russell DW (2001) Molecular cloning: a laboratory manual, 3rd edn. Cold Spring Harbor Lab Press, Plainview
27. Yuping X, Lili M, Chengbo H, Jinyi L, Lei X (2007) MSI/LOH and extron expression of the FHIT gene in gastric carcinoma. Front Med China 1(1):99-103
28. Preacher KJ (2001) Calculation for the chi-square test: An interactive calculation tool for chi-square tests of goodness of fit and independence [Computer software]. Available from http://www.quantpsy.org.
29. Hansen MF, Cavenee WK (1987) Genetics of cancer predeposition. Cancer Res 47:5518-5527
30. Kim S, Domon-Dell C, Wang Q, Chung DH, Di Cristofano A, Pandolfi PP, Freund JN, Evers BM (2002) PTEN and TNFalpha regulation of the intestinal-specific Cdx-2 homeobox gene through a PI3K, PKB/Akt, and NF-kappaB-dependent pathway. Gastroenterology 123:1163-1178
31. McConnachie G, Pass I, Walker SM, Downes CP (2003) Interfacial kinetic analysis of the tumour suppressor phosphatase, PTEN: evidence for activation by anionic phospholipids. Biochem J 371(3):947-955
32. Brown KS, Blair D, Reid SD, Nicholson EK, Harnett MM (2004) FcgammaRIIb-mediated negative regulation of BCR signaling is associated with the recruitment of the MAPKinasephosphatase, Pac-1, and the 3′-inositol phosphatase, PTEN. Cell Signal 16:71-80
33. Cho SH, Lee CH, Ahn Y, Kim H, Kim H, Ahn CY, Yang KS, Lee SR (2004) Redox regulation of PTEN and protein tyrosine phosphatases in H(2)O(2) mediated cell signaling. FEBS Lett 560:7-13
34. Wishart MJ, Dixon JE (2002) PTEN and myotubularin phosphatases: from 3-phosphoinositide dephosphorylation to disease. Trends Cell Biol 12:579-585
35. Mills GB, Kohn E, Lu Y, Eder A, Fang X, Wang H, Bast RC, Gray J, Jaffe R, Hortobagyi G (2003) Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer. Semin Oncol 30(5 Suppl 16):93-104
36. Orchiston EA, Bennett D, Leslie NR, Clarke RG, Winward L, Downes CP, Safrany ST (2004) PTEN M-CBR3, a versatile and selective regulator of inositol 1,3,4,5,6-pentakisphosphate (Ins (1,3,4,5,6) P5). Evidence for Ins (1,3,4,5,6)P5 as a proliferative signal. J Biol Chem 279:1116-1122
37. Zhao H, Dupont J, Yakar S, Karas M, LeRoith D (2004) PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells. Oncogene 23:786-794
38. Konopka B, Janiec-Jankowska A, Paszko Z, Goluda M (2004) The coexistence of ERBB2, INT2, and CMYC oncogene amplifications and PTEN gene mutations in endometrial carcinoma. J Cancer Res Clin Oncol 130:114-121